Satellite Symposium | Patient with R/R CLL—European perspective

The virtual Lymphoma Hub Satellite Symposium, at this year's European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, brought together an international panel of experts to discuss the management and treatment of patients with relapsed and/or refractory (R/R) lymphoma. Here, Professor Francesc Bosch, University Hospital Vall d'Hebron, Barcelona, ES, outlines how he would manage a patient with R/R chronic lymphocytic leukemia (CLL) following relapse to venetoclax + rituximab.

Professor Francesc Bosch discusses the mechanisms of progression under venetoclax, and predictive biomarkers for prognosis following targeted therapy. He recommends transition to Bruton's tyrosine kinase (BTK) inhibitor therapy for the selected patient case, and highlights the value of ibrutinib treatment in patients with R/R CLL previously treated with venetoclax in the MURANO study.

Francesc Bosch also discusses the potential benefit of treatment with Pi3K inhibitors and experimental chimeric antigen receptor (CAR) T-cell therapy in patients with R/R CLL who have received prior venetoclax.